Kazakhstan vs Mozambique: Average cost of drugs for extensively drug-resistant tuberculosis
Kazakhstan
6,329 constant 2022 US$
in 2023
Mozambique
5,675 constant 2022 US$
in 2024
Kazakhstan rank
5th
Mozambique rank
7th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Kazakhstan
- Mozambique
How they compare
Kazakhstan currently reports 6,329 constant 2022 US$ against 5,675 constant 2022 US$ in Mozambique, a difference of 654 constant 2022 US$.
That makes Kazakhstan's figure about 1.1 times Mozambique's.
The two have swapped places 4 times across 7 shared years of data; in 2017 it was Kazakhstan ahead.
Kazakhstan ranks 5th and Mozambique ranks 7th of 56 countries.
Kazakhstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kazakhstan | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,871 constant 2022 US$ | 3,564 constant 2022 US$ | 307 constant 2022 US$ | Kazakhstan |
| 2020s | 4,806 constant 2022 US$ | 4,753 constant 2022 US$ | 52.25 constant 2022 US$ | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Kazakhstan or Mozambique?
- Kazakhstan, at 6,329 constant 2022 US$ against 5,675 constant 2022 US$ in Mozambique as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Kazakhstan and Mozambique?
- 654 constant 2022 US$, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Mozambique?
- 7 years are reported by both, from 2017 to 2023.
- How do Kazakhstan and Mozambique rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Kazakhstan ranks 5th and Mozambique ranks 7th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.